Table 4 Univariate and multivariable analysis of risk factors for vascular events (arterial/venous thrombosis and hemorrhage) after diagnosis among 985 patients with essential thrombocythemia (ET), fully annotated for driver mutations with CALR mutation type.
From: One thousand patients with essential thrombocythemia: the Mayo Clinic experience
Follow-up in years, median (range): 8.5 (0.01–52.7) | Arterial thrombosis-free survival | Venous thrombosis-free survival | Hemorrhage-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
Events; n (%): 125 (13) | Events; n (%): 72 (7) | Events; n (%): 107/968 (11) | |||||||
Driver mutations | Univariate P value HR (95% CI) | Age-adjusted P value HR (95% CI) | Gender-adjusted P value HR (95% CI) | Univariate P value HR (95% CI) | Age-adjusted P value HR (95% CI) | Gender-adjusted P value HR (95% CI) | Univariate P value HR (95% CI) | Age-adjusted P value HR (95% CI) | Gender-adjusted P value HR (95% CI) |
JAK2 vs type 1 CALR | 0.12 1.5 (0.9–2.6) | 0.37 | 0.05 1.7 (1.0–2.9) | 0.14 1.7 (0.8–3.5) | 0.19 1.6 (0.8–3.3) | 0.06 1.9 (0.9–4.1) | 0.08 1.7 (0.9–3.2) | 0.21 | 0.05 1.9 (1.0–3.5) |
JAK2 vs type 2 CALR | 0.32 | 0.81 | 0.21 | 0.50 | 0.64 | 0.36 | 0.37 | 0.77 | 0.29 |
JAK2 vs MPL | 0.99 | 0.67 | 0.88 | 0.99 | 0.99 | 0.99 | 0.12 0.51 (0.2–1.2) | 0.25 | 0.15 0.54 (0.2–1.3) |
JAK2 vs triple negative | 0.02 3.0 (1.2–7.5) | 0.04 2.6 (1.03–6.3) | 0.02 3.0 (1.2–7.4) | 0.03 4.9 (1.2–20.2) | 0.03 4.6 (1.1–19.0) | 0.03 4.9 (1.2–20.2) | 0.12 1.9 (0.8–4.1) | 0.25 | 0.12 1.8 (0.8–4.0) |
Type 1 CALR vs Type 2 CALR | 0.73 | 0.64 | 0.65 | 0.54 | 0.52 | 0.46 | 0.58 | 0.49 | 0.52 |
Type 1 CALR vs MPL | 0.46 | 0.96 | 0.41 | 0.99 | 0.99 | 0.99 | 0.02 0.29 (0.1–0.8) | 0.08 0.4 (0.2–1.1) | 0.01 0.3 (0.1–0.8) |
Type 2 CALR vs MPL | 0.61 | 0.80 | 0.61 | 0.99 | 0.99 | 0.99 | 0.06 0.4 (0.1–1.0) | 0.26 | 0.06 0.4 (0.1–1.1) |
Type 1 CALR vs triple negative | 0.18 1.9 (0.7–5.4) | 0.18 1.9 (0.7–5.5) | 0.28 | 0.17 2.9 (0.6–13.5) | 0.18 2.9 (0.6–13.3) | 0.25 | 0.86 | 0.88 | 0.96 |
Type 2 CALR vs triple negative | 0.12 2.3 (0.81–6.4) | 0.10 2.4 (0.84–6.7) | 0.17 2..1 (0.7–5.9) | 0.08 3.9 (0.8–17.9) | 0.08 3.9 (0.8–18.1) | 0.11 3.5 (0.8–16.3) | 0.52 | 0.46 | 0.61 |
MPL vs triple negative | 0.10 3.0 (0.81–11.2) | 0.28 | 0.13 2.8 (0.7–10.4) | 0.99 | 0.99 | 0.99 | 0.02 3.6 (1.2–10.9) | 0.09 2.6 (0.9–7.6) | 0.03 3.4 (1.1–10.2) |
